Zogenix to Participate in the 20th Annual Needham Virtual Healthcare Conference

EMERYVILLE, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and Chief Executive Officer, and Michael Smith, Executive Vice President, Chief Financial Officer, and Treasurer, will participate in a fireside chat on Monday, April 12, 2021, at the 20th Annual Needham Virtual Healthcare Conference.

The presentation will be webcast live and archived for 90 days on Zogenix's Investor Relations website at https://zogenixinc.gcs-web.com.

About ZogenixZogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company’s first rare disease therapy, FINTEPLA® (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency. Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.

CONTACTS:

ZogenixMelinda BakerSenior Director, Corporate Communications+1 (510) 788-8732 | [email protected]

InvestorsBrian Ritchie Managing Director, LifeSci Advisors LLC+1 (212) 915-2578 | [email protected]

MediaStefanie Tuck, Vice President, Porter Novelli+1 (978) 390-1394 | [email protected]

You May Also Be Interested In

• The deadline for Valoe’s restructuring programme extended until 14.6.2024. Valoe has secured financing for the duration of the proceedings and continues to negotiate longer-term financing.
• Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1
• Gold79 Announces Effective Date of Previously Announced Share Consolidation